Premium
Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans
Author(s) -
van Barlingen H. H. J. J.,
van Beek A.,
Erkelens D. W.,
de Bruin T. W. A.
Publication year - 1997
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1046/j.1365-2796.1997.00157.x
Subject(s) - lipoprotein lipase , antithrombotic , pharmacology , medicine , heparin , hepatic lipase , anticoagulant , adipose tissue
van Barlingen HHJJ, van Beek A, Erkelens DW, de Bruin TWA (Department of Internal Medicine, Laboratory of Lipid Metabolism, University Hospital, Utrecht University, PO Box 85 500, 3508 GA Utrecht, The Netherlands). Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans. J Intern Med 1997; 242 : 125–29. Objectives Heparin is a widely used antithrombotic drug. Besides its anticoagulant properties, it also has a marked influence on lipid metabolism, by decreasing serum lipolytic activity due to lipase depletion from vascular sites and stores. Especially in haemodialysis patients who receive heparin during every dialysis session, and in hypertriglyceridaemic patients, decreasing lipolytic activity can lead to the accumulation of triglyceride‐rich lipoproteins, which are atherogenic. Replacement of heparin by an antithrombotic drug with less lipase releasing activity might reduce this risk. Design We tested danaparoid, a new antithrombotic drug, and compared its ability to displace biotinylated heparan sulphate from lipoprotein lipase in vitro with heparin. Furthermore we compared the in vivo lipase releasing activity. Results Danaparoid displaced significantly less biotinylated heparan sulphate from triglyceride‐rich lipoprotein‐lipoprotein lipase complexes in vitro than heparin. Intravenous injection of danaparoid released less than 20% ( P < 0.05) of the lipolytic activity released by an equivalent anticoagulant dose of heparin. Conclusion Danaparoid is the drug of choice during the antithrombotic therapy of hypertriglyceridaemic or haemodialysis patients.